Bristol-Myers Squibb Loses $6 Billion in Value on Celgene Deal Setback: Brainstorm Health

Happy Monday, readers! Bristol-Myers Squibb hasn’t exactly had a pristine path to its proposed acquisition of Celgene. Sure, the legacy pharma giant racked up more than 75% of shareholder votes to approve the $74 billion acquisition following a quickly-quashed rebellion from some activist naysayers. But the company hit another hurdle in its Celgene acquisition quest […]